Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020

January 17, 2020

PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 17 January 2020 – Laura van ‘t Veer, Ph.D., co-founder of Agendia Inc. and developer of MammaPrint, the 70-gene risk of recurrence assay for breast…

Read more

Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse

January 3, 2020

PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse   IRVINE, CALIF., U.S. and Amsterdam – 3 January 2020 – Agendia Inc., a world leader in precision oncology for breast cancer, announces that one of the largest healthcare insurers in Germany, Techniker Krankenkasse, has joined the Selective…

Read more

PROMIS study findings presented at SABCS 2019

December 23, 2019

PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal Women with Early-Stage Breast Cancer   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, December 12, 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today new data comparing genomic profiling results for patients under the age of 50 with early-stage breast…

Read more

Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients

November 19, 2019

PRESS RELEASE Data evaluating MammaPrint® and BluePrint® includes new risk analysis of premenopausal women with breast cancer, and insights into unique characteristics among specific populations of breast cancer patients   IRVINE, CALIF. – 19 November 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that five abstracts featuring data…

Read more